Genzyme would like to take this opportunity to provide a brief update to the Pompe patient community regarding the US

MTAP, the Myozyme® (alglucosidase alfa) Temporary Access Program, is a clinical program to provide access to Myozyme produced by a

As many of you are aware, a standard part of the biologics drug development process is to incrementally scale-up manufacturing

2006 AMDA/IPA Conference Report By Allan Muir With contributions from George Fox and Jared Salbato Friday—November 17, 2006 Texas Hoe

Pompe Workshop Report Allan Muir, Pompe Representative, AGSD(UK) On October the 16th this year we held our annual AGSD (UK)